Expert Opinion on Investigational Drugs, Volume 22, Issue 4 (2013)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 22, Issue 4 (2013)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Volume 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Editorial

Editorial
Agomelatine, melatonin and depressive disorder
Trevor R Norman
Pages: 407-410
Published online: 13 Mar 2013
AbstractforAgomelatine, melatonin and depressive disorder | Full Text | References | PDF (163.7 KB)
  • 3331 Views
  • 3 CrossRef citations
  • 0Altmetric
Free Access

Reviews

Review Article
5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders
Tiago A Mestre MD MSc, Mateusz Zurowski FRCP & Susan H Fox MRCP PhD
Pages: 411-421
Published online: 15 Feb 2013
Abstractfor5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders | Full Text | References | PDF (236.1 KB)
  • 1089 Views
  • 46 CrossRef citations
  • 0Altmetric
Review Article
Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation
Peter SE Davies MBChB, Simon M Graham MBChB MRCS, Robert J MacFarlane MBChB MRCS, Andreas Leonidou MBChB MRCS, Athanasios Mantalaris BSc PhD & Eleftherios Tsiridis MD MSc PhD FRCS
Pages: 423-441
Published online: 14 Feb 2013
AbstractforDisease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation | Full Text | References | PDF (263.4 KB)
  • 870 Views
  • 26 CrossRef citations
  • 0Altmetric
Review Article
Optimizing biologically targeted clinical trials for neurofibromatosis
David H Gutmann MD PhD, Jaishri O Blakeley MD, Bruce R Korf MD PhD & Roger J Packer MD
Pages: 443-462
Published online: 21 Feb 2013
AbstractforOptimizing biologically targeted clinical trials for neurofibromatosis | Full Text | References | PDF (883.5 KB)
  • 486 Views
  • 68 CrossRef citations
  • 0Altmetric
Review Article
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
William N Washburn & Simon M Poucher BSc (Hons) PhD FBPharmacolS
Pages: 463-486
Published online: 01 Mar 2013
AbstractforDifferentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus | Full Text | References | PDF (545.2 KB)
  • 2488 Views
  • 65 CrossRef citations
  • 0Altmetric
Review Article
Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
Lauren M Cornall, Michael L Mathai, Deanne H Hryciw & Andrew J McAinch
Pages: 487-498
Published online: 27 Feb 2013
AbstractforIs GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases? | Full Text | References | PDF (506.4 KB)
  • 665 Views
  • 17 CrossRef citations
  • 0Altmetric
Review Article
Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis
Sushmita Chakraborty PhD, Puneet Chopra PhD, Anushree Hak B Tech, Sunanda Ghosh Dastidar PhD & Abhijit Ray PhD
Pages: 499-515
Published online: 13 Mar 2013
AbstractforHepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis | Full Text | References | PDF (756.3 KB)
  • 590 Views
  • 42 CrossRef citations
  • 0Altmetric
Review Article
Opioid antagonists for pain
Robert Taylor Jr PhD, Joseph V Pergolizzi Jr MD, Frank Porreca PhD & Robert B Raffa PhD
Pages: 517-525
Published online: 13 Mar 2013
AbstractforOpioid antagonists for pain | Full Text | References | PDF (314.5 KB)
  • 576 Views
  • 11 CrossRef citations
  • 0Altmetric

Drug Evaluations

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection
David Alan Herbst Jr BA & K Rajender Reddy MD
Pages: 527-536
Published online: 01 Mar 2013
Abstractfor Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection | Full Text | References | PDF (434.4 KB)
  • 1371 Views
  • 64 CrossRef citations
  • 0Altmetric
Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?
Meihui Chen, Anmin Liu, Ying Ouyang, Yingjuan Huang, Xiaojuan Chao & Rongbiao Pi
Pages: 537-550
Published online: 05 Mar 2013
Abstractfor Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? | Full Text | References | PDF (573.3 KB)
  • 823 Views
  • 65 CrossRef citations
  • 0Altmetric

Research Article

Article
Related articles
Page: i
Published online: 13 Mar 2013
CitationforRelated articles | Full Text | PDF (132.1 KB)
  • 394 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Explore articles

Explore the most recently published articles

Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents
Charanjit Kaur et al.
Review Article | Published online: 3 Aug 2024
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies
Enrica Antonia Martino et al.
Review Article | Published online: 3 Aug 2024
An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions
Ezzat A. Ismail et al.
Review Article | Published online: 3 Aug 2024
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations
Ruben Casado-Arroyo et al.
Review Article | Published online: 3 Aug 2024
View all latest articles